AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alvotech Receives EU Marketing Authorization for AVT03, a Biosimilar to Prolia and Xgeva
ByAinvest
Monday, Nov 24, 2025 5:31 am ET1min read
Alvotech has received marketing authorization in Europe for AVT03, a biosimilar of Prolia and Xgeva, which contain the active ingredient denosumab. The biosimilar is used to treat bone loss and osteoporosis, and has a market value of approximately $150 million in the last 12 months. The company plans to increase access to these medications by offering a lower-cost alternative. The biosimilar will be marketed by Alvotech's partners STADA and Dr. Reddy's Laboratories.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet